DANHEART (H-HeFT and Met-HeFT)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1100 participants.
Also called NCT03514108
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,100 participants
- Sponsor
- Registry
-
NCT03514108 -
2015-002150-12
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Denmark
- Registry status
- Completed
Technical summary
Registry record NCT03514108. Randomized; quadruple masking; primary purpose treatment. Start 2018-03-01 (actual); primary completion 2025-12-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- DANHEART (H-HeFT and Met-HeFT)
- Acronym
- DANHEART
- Condition
- Heart Failure
- Condition
- Diabetes
- Intervention (Drug)
- Hydralazine Isosorbide Dinitrate
- Intervention (Drug)
- Placebo Oral Tablet
- Intervention (Drug)
- Metformin Hydrochloride
- Intervention (Drug)
- Placebo Oral Tablet
- Lead sponsor
- Henrik Wiggers
- Collaborator
- Danish Heart Foundation
- Collaborator
- Danish Council for Independent Research
- Collaborator
- The Danish Regions: Foundation for Medical Research
- Collaborator
- Novo Nordisk Foundation
- Collaborator
- The Aase og Ejnar Danielsen Foundation
Record details
- Record id
cardio:ct-nct03514108- Content hash
1113958da1e3af6b9ee67ec344e9b4fa905694e38e9efca67d2a67b70afdec59